...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >Dolutegravir: An Integrase Strand Transfer Inhibitor for the Treatment of Human Immunodeficiency Virus I in Adults
【24h】

Dolutegravir: An Integrase Strand Transfer Inhibitor for the Treatment of Human Immunodeficiency Virus I in Adults

机译：Dolutegravir：用于治疗成人免疫缺陷病毒I的整合酶链转移抑制剂。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To review the efficacy, safety, pharmacokinetics, pharmacodynamics, administration, drug interactions, and cost of dolutegravir (Tivicay), a third in class integrase strand transfer inhibitor (INSTI), for the treatment of human immunodeficiency virus (HIV-1) in adults. Data Sources: MEDLINE, International Pharmaceutical Abstracts, ClinicalTrials. gov, and Google Scholar searches (January 2000 to May 2014) were conducted for articles published in English and limited to human subjects, using the key words antiretroviral drugs, HIV integrase strand transfer inhibitors, dolutegravir, DTG, and S/GSK1349572. Study Selection and Data Extraction: Following MEDLINE, International Pharmaceutical Abstracts, ClinicalTrials.gov, and Google Scholar searches, 6 clinical trials were identified and included in this review. Phase III/ IV studies evaluating the safety and efficacy of dolutegravir in humans were selected and evaluated. Data Synthesis: In treatment naive and experienced patients dolutegravir was noninferior to raltegravir at suppressing viral load when added to background therapy. Abacavir/lamivudine/dolutegravir was noninferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate and darunavir/ritonavir plus background therapy at suppressing viral load. In patients with multiple-class antiretroviral resistance at baseline, dolutegravir decreased HIV RNA by 1.4 log_10 copies/mL at day 8, 63% of patients had achieved virologic suppression at week 8, and retained potency in treatment-experienced INSTI-resistant patients up to week 48 or 96 of follow-up. Conclusion: Dolutegravir is a safe, effective, and well-tolerated treatment option for adults with HIV-1, even in the setting of resistance to other antiretrovirals.
机译：目的：综述第三类整合酶链转移抑制剂（INSTI）多洛格韦（Tivicay）治疗人类免疫缺陷病毒（HIV-1）的功效，安全性，药代动力学，药物动力学，给药，药物相互作用和成本在成人中。数据来源：MEDLINE，国际药物文摘，临床试验。 gov和Google Scholar搜索（2000年1月至2014年5月）使用关键词为抗逆转录病毒药物，HIV整合酶链转移抑制剂，dolutegravir，DTG和S / GSK1349572进行，以英语发表，并且仅限于人类受试者。研究选择和数据提取：在MEDLINE，International Pharmaceutical Abstracts，ClinicalTrials.gov和Google Scholar搜索之后，确定了6项临床试验并将其纳入本评价。选择和评估了评价多洛格韦在人体内的安全性和有效性的III / IV期研究。数据综合：在初治和有经验的患者中，当加入背景治疗时，dolutegravir在抑制病毒载量方面不亚于raltegravir。阿巴卡韦/拉米夫定/ dolutegravir在抑制病毒载量方面不逊于依非韦伦/恩曲他滨/替诺福韦富马酸替索洛韦和达鲁那韦/利托那韦加背景疗法。在基线时具有多类抗逆转录病毒耐药性的患者中，多洛格韦在第8天时将HIV RNA降低1.4 log_10拷贝/ mL，在第8周时有63％的患者实现了病毒学抑制，并且在经历过治疗的INSTI耐受性患者中保留了效力，直至随访的第48周或第96周。结论：即使在对其他抗逆转录病毒药物有抗药性的情况下，Dolutegravir对成人HIV-1也是一种安全，有效且耐受性良好的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号